Holen Sie sich die Stockscreener-App
9.495
3.11%
-0.305
Schlusskurs vom Vortag:
$9.80
Offen:
$9.11
24-Stunden-Volumen:
2,126
Relative Volume:
0.01
Marktkapitalisierung:
$8.71M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.13M
KGV:
-0.0392
EPS:
-242.0756
Netto-Cashflow:
$-14.52M
1W Leistung:
-1.09%
1M Leistung:
+3.09%
6M Leistung:
-11.26%
1J Leistung:
-54.30%
1-Tages-Spanne:
$9.11
$9.835
1-Wochen-Bereich:
$8.898
$9.99
52-Wochen-Spanne:
$6.0829
$46.76
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Firmenname
Transcode Therapeutics Inc
Sektor
Branche
Telefon
857-301-6857
Adresse
6 LIBERTY SQUARE, BOSTON
Compare RNAZ vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
9.50 | 8.99M | 0 | -27.13M | -14.52M | -242.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.84 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.46 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.22 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Transcode Therapeutics Inc Aktie (RNAZ) Neueste Nachrichten
How interest rate cuts could boost TransCode Therapeutics Inc. stockWeekly Profit Analysis & Safe Swing Trade Setup Alerts - Naître et grandir
Bank Watch: Is TransCode Therapeutics Inc a good ESG investmentJuly 2025 Decliners & Risk Managed Investment Signals - baoquankhu1.vn
Aug Macro: Can TransCode Therapeutics Inc disrupt its industryJuly 2025 Chart Watch & Real-Time Stock Movement Alerts - baoquankhu1.vn
Aug Weekly: Is TransCode Therapeutics Inc a speculative investmentTrend Reversal & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138 - Revista ADVFN
TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset - Stocktwits
TransCode Therapeutics Expands Pipeline With Oncolytic Virus Deal - TipRanks
TransCode Therapeutics (NASDAQ: RNAZ) adds Unleash oncolytic platform in all-stock licensing deal - Stock Titan
TransCode licenses bladder cancer therapy platform from Unleash - Investing.com
Precision Trading with Transcode Therapeutics Inc. (RNAZ) Risk Zones - Stock Traders Daily
TransCode Therapeutics Incenters exclusive license agreement with Unleash - marketscreener.com
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of - PR Newswire
RNAZTransCode Therapeutics Announces Strategic Expansion of its Product Portfolio - mx.advfn.com
RNAZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TransCode Therapeutics Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules - mx.advfn.com
TransCode Therapeutics (NASDAQ:RNAZ) Shares Up 0.8% – Still a Buy? - Defense World
Fed Watch: Is TransCode Therapeutics Inc showing insider buyingPortfolio Risk Summary & Weekly Setup with High ROI Potential - baoquankhu1.vn
Buyout Rumor: Why is TransCode Therapeutics Inc stock going downEarnings Overview Report & AI Powered Market Entry Strategies - baoquankhu1.vn
Aug Gainers: Is TransCode Therapeutics Inc subject to activist investor interestMarket Growth Report & Risk Controlled Daily Trade Plans - baoquankhu1.vn
TransCode Unveils Tumor-Selective RIG-I Agonist Imaging Strategy - TipRanks
TransCode Therapeutics publishes preclinical RIG-I agonist study showing tumor-selective activation, supports TTX platform - TradingView
TransCode Therapeutics (RNAZ) highlights RIG-I cancer immunotherapy study in 8-K - Stock Titan
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development - PR Newswire
New cancer approach uses tumor RNA to trigger immune attack in cells - Stock Titan
Will TransCode Therapeutics Inc. stock benefit from green energy trendsQuarterly Trade Summary & Free Reliable Trade Execution Plans - mfd.ru
Technical Reactions to RNAZ Trends in Macro Strategies - Stock Traders Daily
Technical Analysis: Whats the beta of TransCode Therapeutics Inc stockJuly 2025 Closing Moves & Daily Oversold Bounce Ideas - baoquankhu1.vn
Checkpoint Inhibitors Competitive Landscape Report 2026: Comprehensive Insights About 50+ Companies and 60+ Drugs - GlobeNewswire Inc.
Sell Signal: Can TransCode Therapeutics Inc benefit from deglobalizationCEO Change & Technical Entry and Exit Alerts - baoquankhu1.vn
Is TransCode Therapeutics Inc. stock a top momentum playJuly 2025 Decliners & Low Risk Growth Stock Ideas - mfd.ru
Can TransCode Therapeutics Inc. sustain its profitability2025 Major Catalysts & Intraday High Probability Setup Alerts - mfd.ru
Why is TransCode Therapeutics Inc. stock going downMarket Sentiment Review & Weekly High Conviction Ideas - mfd.ru
Movement Recap: Is TransCode Therapeutics Inc showing insider buyingWeekly Trade Analysis & Community Consensus Trade Alerts - baoquankhu1.vn
Aug Selloffs: Will TransCode Therapeutics Inc benefit from geopolitical trendsProfit Target & Smart Investment Allocation Insights - baoquankhu1.vn
Can TransCode Therapeutics Inc. disrupt its industryPortfolio Update Report & AI Powered Buy and Sell Recommendations - mfd.ru
What’s the beta of TransCode Therapeutics Inc. stockJuly 2025 Sentiment & Daily Stock Trend Watchlist - mfd.ru
ETF Watch: How correlated is FBYDW to the S P500July 2025 Outlook & Real-Time Volume Spike Alerts - baoquankhu1.vn
TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial - TechStock²
Therapeutics, Inc. (RNAZ) Stock: Jumps as Company Expands RNA Cancer Program into Colorectal Indication - parameter.io
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
TransCode Therapeutics Unveils Promising Glioblastoma Data with TTX-MC138 - timothysykes.com
TransCode Therapeutics’ TTX-MC138 Excites Market with Promising Glioblastoma Data - StocksToTrade
TransCode Therapeutics: Promising Data Boosts Future Outlook - timothysykes.com
TransCode Therapeutics Advances Phase 2a Colorectal Cancer Trial - TipRanks
TransCode Therapeutics Announces IND Amendment for Phase 2a Trial - TradingView
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial With TTX-MC138 - 富途牛牛
Gainers Report: Does TransCode Therapeutics Inc have pricing powerRisk Management & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Risk Analysis: Whats the beta of TransCode Therapeutics Inc stockJuly 2025 Spike Watch & Smart Allocation Stock Reports - baoquankhu1.vn
Aug Intraday: What’s the beta of TransCode Therapeutics Inc. stock2025 Trading Recap & Free Weekly Watchlist of Top Performers - mfd.ru
What are analysts’ price targets for TransCode Therapeutics Inc.July 2025 Patterns & Entry Point Strategy Guides - mfd.ru
Earnings Recap: Is TransCode Therapeutics Inc a good stock for dollar cost averagingPortfolio Performance Summary & Weekly Breakout Watchlists - baoquankhu1.vn
Finanzdaten der Transcode Therapeutics Inc-Aktie (RNAZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):